El Grupo Menarini presenta datos del ensayo de fase 3 SENTRY de selinexor más ruxolitinib en mielofibrosis ...Middle East

- El Grupo Menarini presenta datos del ensayo de fase 3 SENTRY de selinexor más ruxolitinib en mielofibrosis en el Congreso de la Asociación Europea de Hematología (EHA) 2026 La combinación de selinexor y ruxolitinib alcanzó el primer criterio de valoración coprimario, demostrando una...

Hence then, the article about el grupo menarini presenta datos del ensayo de fase 3 sentry de selinexor mas ruxolitinib en mielofibrosis was published today ( Monday 15/06/2026 - 02:50 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( El Grupo Menarini presenta datos del ensayo de fase 3 SENTRY de selinexor más ruxolitinib en mielofibrosis )

Also on site :

• Anne Schedeen Dies: Actress Who Played ‘ALF’s Mom Was 77
• Russian MOD confirms strikes on Ukrainian military facilities: What we know so far
• Trump allies cheer Iran deal announcement as Democrats call for clarity